These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35222031)

  • 1. Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis.
    Wang P; Deng J; Zhang Q; Feng H; Zhang Y; Lu Y; Han L; Yang P; Deng Z
    Front Pharmacol; 2022; 13():817119. PubMed ID: 35222031
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of non-prostanoid prostacyclin receptor agonist for pulmonary hypertension: A meta-analysis.
    Wang P; Feng H; Guo Y; Wu N; Yin H; Zhang Y; Pei S; Gao J; Lu Y; Hu Y; Zhang Y; Deng Z
    Pulm Pharmacol Ther; 2023 Feb; 78():102182. PubMed ID: 36460268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Tremblay É; Gosselin C; Mai V; Lajoie AC; Kilo R; Weatherald J; Lacasse Y; Bonnet S; Lega JC; Provencher S
    Circulation; 2022 Aug; 146(8):597-612. PubMed ID: 35862151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension.
    Dang ZC; Tang B; Li B; Liu S; Ge RL; Li ZQ; Lu DX
    Exp Ther Med; 2019 Dec; 18(6):4740-4746. PubMed ID: 31798703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis.
    Li T; Chen Y; Zang W; Geng N; Ma S; Li X
    Curr Med Res Opin; 2013 Aug; 29(8):889-99. PubMed ID: 23647397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostanoids for pulmonary arterial hypertension.
    Galiè N; Manes A; Branzi A
    Am J Respir Med; 2003; 2(2):123-37. PubMed ID: 14720012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review.
    Alqarni AA; Aldhahir AM; Bintalib HM; Alqahtani JS; Siraj RA; Majrshi M; AlGarni AA; Naser AY; Alghamdi SA; Alwafi H
    Front Med (Lausanne); 2023; 10():1217156. PubMed ID: 37706024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
    Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
    Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of oral targeted treatments in pulmonary arterial hypertension: A systematic review and meta-analysis.
    Zhu HR; Kuang HY; Li Q; Ji XJ
    Front Cardiovasc Med; 2022; 9():915470. PubMed ID: 35983180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of exercise-based pulmonary rehabilitation on adults with asthma: a systematic review and meta-analysis.
    Feng Z; Wang J; Xie Y; Li J
    Respir Res; 2021 Jan; 22(1):33. PubMed ID: 33516207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.
    Galiè N; Humbert M; Vachiéry JL; Vizza CD; Kneussl M; Manes A; Sitbon O; Torbicki A; Delcroix M; Naeije R; Hoeper M; Chaouat A; Morand S; Besse B; Simonneau G;
    J Am Coll Cardiol; 2002 May; 39(9):1496-502. PubMed ID: 11985913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary Vasodilator Therapy in Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (Severe PH-COPD): A Systematic Review and Meta-Analysis.
    Elkhapery A; Hammami MB; Sulica R; Boppana H; Abdalla Z; Iyer C; Taifour H; Niu C; Deshwal H
    J Cardiovasc Dev Dis; 2023 Dec; 10(12):. PubMed ID: 38132665
    [No Abstract]   [Full Text] [Related]  

  • 16. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 17. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis.
    Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G
    Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials.
    Tan Z; Wu PY; Zhu TT; Su W; Fang ZF
    Pulm Pharmacol Ther; 2022 Oct; 76():102144. PubMed ID: 35918025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
    McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
    Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of oral targeted therapies in pulmonary arterial hypertension: a meta-analysis of randomized clinical trials.
    Zheng YG; Ma H; Chen L; Jiang XM; Zhou L; Lin S; Chen SL
    Pulm Circ; 2018; 8(4):2045894018798183. PubMed ID: 30124134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.